Collectively, the results suggest that the NEK2 inhibitor enhanced the efficacy of PD-L1 blockade both in vitro and in vivo, alleviating immuno-resistance in pancreatic cancer. This evidence concerns the gene NEK2 and pancreatic neoplasm.